A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group
- PMID: 8538704
- DOI: 10.1056/NEJM199602083340601
A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group
Abstract
Background: Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low.
Methods: We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis (manufactured by Connaught Laboratories); or diphtheria and tetanus toxoids without pertussis (DT). The acellular DTP vaccine was either one containing filamentous hemagglutinin, pertactin, and pertussis toxin inactivated with formalin and glutaraldehyde (SmithKline Beecham) or one with filamentous hemagglutinin, pertactin, and genetically detoxified pertussis toxin (Chiron Biocine). Pertussis was defined as 21 days or more of paroxysmal cough, with infection confirmed by culture or serologic testing.
Results: The efficacy of each vaccine, given in three doses, against pertussis was determined for 14,751 children over an average of 17 months, with cases included in the analysis if cough began 30 days or more after the completion of immunization. For both of the acellular DTP vaccines, the efficacy was 84 percent (95 percent confidence intervals, 76 to 89 percent for Biocine DTP and 76 to 90 percent for SmithKline DTP), whereas the efficacy of the whole-cell DTP vaccine was only 36 percent (95 percent confidence interval, 14 to 52 percent). The antibody responses were greater to the acellular vaccines than to the whole-cell vaccine. Local and systemic adverse events were significantly more frequent after the administration of the whole-cell vaccine. For the acellular vaccines, the frequency of adverse events was similar to that in the control (DT) group.
Conclusions: The two acellular DTP vaccines we studied were safe, immunogenic, and efficacious against pertussis, whereas the efficacy of the whole-cell DTP vaccine was unexpectedly low.
Comment in
-
Acellular pertussis vaccines for infants.N Engl J Med. 1996 Feb 8;334(6):391-2. doi: 10.1056/NEJM199602083340609. N Engl J Med. 1996. PMID: 8538712 No abstract available.
Similar articles
-
A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.N Engl J Med. 1996 Feb 8;334(6):349-55. doi: 10.1056/NEJM199602083340602. N Engl J Med. 1996. PMID: 8538705 Clinical Trial.
-
A placebo-controlled trial of a pertussis-toxoid vaccine.N Engl J Med. 1995 Oct 19;333(16):1045-50. doi: 10.1056/NEJM199510193331604. N Engl J Med. 1995. PMID: 7675047 Clinical Trial.
-
Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.Dev Biol Stand. 1997;89:113-8. Dev Biol Stand. 1997. PMID: 9272341 Clinical Trial.
-
[The immunological basis of the administration of DTP-polio vaccine].Verh K Acad Geneeskd Belg. 2000;62(4):245-67. Verh K Acad Geneeskd Belg. 2000. PMID: 11004905 Review. Dutch.
-
Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.Paediatr Drugs. 2000 Mar-Apr;2(2):139-59. doi: 10.2165/00148581-200002020-00007. Paediatr Drugs. 2000. PMID: 10937466 Review.
Cited by
-
Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.Vaccine. 2024 Jan 12;42(2):383-395. doi: 10.1016/j.vaccine.2023.11.042. Epub 2023 Dec 7. Vaccine. 2024. PMID: 38061956 Free PMC article.
-
Seroprevalence Study of Conserved Enterotoxigenic Escherichia coli Antigens in Globally Diverse Populations.Microorganisms. 2023 Aug 31;11(9):2221. doi: 10.3390/microorganisms11092221. Microorganisms. 2023. PMID: 37764065 Free PMC article.
-
Repeated Bordetella pertussis Infections Are Required to Reprogram Acellular Pertussis Vaccine-Primed Host Responses in the Baboon Model.J Infect Dis. 2024 Feb 14;229(2):376-383. doi: 10.1093/infdis/jiad332. J Infect Dis. 2024. PMID: 37565807 Free PMC article.
-
Pasteurian Contributions to the Study of Bordetella pertussis Toxins.Toxins (Basel). 2023 Feb 25;15(3):176. doi: 10.3390/toxins15030176. Toxins (Basel). 2023. PMID: 36977067 Free PMC article. Review.
-
Antigen Discovery for Next-Generation Pertussis Vaccines Using Immunoproteomics and Transposon-Directed Insertion Sequencing.J Infect Dis. 2023 Feb 14;227(4):583-591. doi: 10.1093/infdis/jiac502. J Infect Dis. 2023. PMID: 36575950 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical